iproplatin (JM9)

RN given refers to cpd without isomeric designation

Also Known As:

JM9; CHIP organoplatinum compound; cis,trans,cis-dichlororidodihydroxidobis(isopropylamine)platinum(IV); cis-dichlorobis(isopropylamine)trans-dihydroxyplatinum IV; dichlorobis(isopropylamine)dihydroxyplatinum IV; iproplatin, (OC-6-33)-isomer; (OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum

Networked: 64 relevant articles (2 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - Organoplatinum Compounds
    - iproplatin: 64

Experts

1.	Browning, Richard: 1 article (12/2021)
2.	Farrer, Nicola J: 1 article (12/2021)
3.	Marsh, Laura K: 1 article (12/2021)
4.	Owen, Joshua: 1 article (12/2021)
5.	Stride, Eleanor: 1 article (12/2021)
6.	Tear, Louise R: 1 article (12/2021)
7.	Thomas, Nia: 1 article (12/2021)
8.	Martín, M: 1 article (10/2001)
9.	Olibera, M: 1 article (03/2001)
10.	Sakamoto, Y: 1 article (03/2001)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 04/01/1989 - "Iproplatin has limited activity in heavily pretreated women with advanced breast carcinoma; further studies in patients less heavily treated may show an improved response rate." 04/01/1989 - "A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer." 06/01/1988 - "Twenty-five women with advanced breast cancer were treated in a phase II trial of iproplatin 275 mg/m2 administered intravenously every 4 weeks. " 12/01/1987 - "Phase II study of iproplatin in metastatic breast carcinoma." 06/01/1988 - "Iproplatin has limited activity in previously treated women with advanced breast cancer."
2.	Neoplasms (Cancer) 07/01/1992 - "Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. " 09/01/1988 - "Iproplatin was administered intravenously over 30 min daily for 5 consecutive days every 3 weeks to 80 evaluable patients with a variety of refractory solid tumor malignancies. " 01/01/1988 - "The growth of cis-DDP-resistant tumors was not influenced by the analog JM9 (4 and 8 mg/kg). " 09/01/1987 - "Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial." 01/01/1991 - "Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer."
3.	Ovarian Neoplasms (Ovarian Cancer) 01/01/1991 - "Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study." 04/01/1985 - "Activity of JM9 in advanced ovarian cancer: a phase I-II trial." 07/01/1991 - "This study shows carboplatin to be more active than iproplatin in the treatment of ovarian cancer and less toxic. " 07/01/1991 - "A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer." 01/01/1988 - "Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant."
4.	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 09/01/1987 - "Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial." 11/01/1992 - "Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT." 11/01/1992 - "Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). " 03/15/1989 - "From these data it is concluded that the antitumor activity of cisplatin may be significantly superior to JM8 and JM9, and results of preclinical investigations should be awaited before replacement of cisplatin by JM8 or JM9 in the treatment of nonseminomatous germ cell tumors can be considered."
5.	Colorectal Neoplasms (Colorectal Cancer) 12/01/1988 - "Phase II trial of iproplatin (CHIP) in previously untreated patients with colorectal cancer." 12/01/1988 - "Iproplatin does not appear to have significant activity against colorectal cancer." 12/01/1988 - "Nineteen previously untreated patients with colorectal cancer and measurable disease were treated with iproplatin (CHIP), 75 mg/m2 daily, for 5 days every 4 weeks for at least 2 courses. " 01/01/1989 - "Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma." 01/01/1989 - "Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin. "

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Cisplatin (Platino)
3.	Fluorouracil (Carac)
4.	Platinum
5.	Cyclophosphamide (Cytoxan)
6.	Epirubicin (Ellence)
7.	Ifosfamide
8.	Drug Combinations
9.	Doxorubicin (Adriamycin)
10.	ormaplatin

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Microbubbles